Evidence map›Paper›PMID 39449341›Full record

ArticleCurrent radiopharmaceuticals2025

Preclinical Aspects of [

Zahra Rohollahi, Seyed Mahmoud Reza Aghamiri, Hassan Yousefnia, Behrouz Alirezapour, Ali Moghaddasi, Samaneh Zolghadri

Abstract read
PubMed Publisher
In one paragraph

Article in Current radiopharmaceuticals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zahra RohollahiDepartment of Medical Radiation Engineering, Shahid Beheshti University, Tehran, Iran.
Seyed Mahmoud Reza AghamiriDepartment of Medical Radiation Engineering, Shahid Beheshti University, Tehran, Iran.
Hassan YousefniaRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
Behrouz AlirezapourRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
Ali MoghaddasiDepartment of Computational and Physical Chemistry, Shahid Beheshti University, Tehran, Iran.
Samaneh ZolghadriRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.

Funding

International Atomic Energy Agency (IAEA) under the Coordinated Research Project F22071, 23763
6 · The paper itself

Abstract

backgroundAn early diagnosis of cancer can lead to choosing more effective treatment and increase the number of cancer survivors. In this study, the preparation and preclinical aspects of [

methodsDFO was conjugated to rituximab monoclonal antibody (mAb), and DFO-rituximab was successfully labeled with zirconium-89 (

resultsThe radiolabeled compound was prepared with radiochemical purity (RCP) >99% (RTLC) and a specific activity of 180±1.8 GBq/g. The RCP of the final complex PBS buffer and human blood serum was higher than 95%, even after 48 h post incubation. The RIA assay demonstrated that more than 63% of the radiolabeled compound (40 ng/ml, 0.5 mL) was bound to 5×10

conclusion[

Indexed as

DeferoxamineImmunoconjugatesLymphoma, Non-HodgkinPositron-Emission TomographyRadioisotopesRadiopharmaceuticalsRituximabZirconiumAnimalsCell Line, TumorCHO CellsCricetulusHumansMiceRatsTissue DistributionDeferoxamineImmunoconjugatesRadioisotopesRadiopharmaceuticalsRituximabZirconiumZirconium-89absorbed doseCD20.DFOnon-hodgkin lymphomaPETraji cell linesrituximab<sup>89</sup>Zr

Identifiers

PMID39449341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.